For hemophiliacs in the developing world who don’t always have access to the same resources and therapy that we are so fortunate to have in the United States, every little bit helps. In this case, though, it’s not just a “little bit.” The National Cancer Coalition (NCC) and Pfizer, Inc have teamed up to donate more than 10 million international units of ReFacto® Antihemophilic Factor – that’s a value of more than $13 million—to the global community.
ReFacto ® is a recombinant therapy, one of many different varieties of factor replacement products, used for the treatment and prevention of bleeding in people with hemophilia A.
The two organizations formed this partnership to address the needs of hemophilia patients around the world—hoping that the donation will not only provide the treatment directly, but also resources to support the development of better infrastructure in areas where patients are treated inadequately or not at all. Generous acts like these are another step toward better health care for all people, regardless of where they live.
For more information, see NCC’s official news release.
Related Posts:
Hemophilia in the Developing World
Sources:
National Cancer Coalition: http://www.nationalcancercoalition.org/
Pfizer, Inc: http://www.pfizer.com/home/
RxList: http://www.rxlist.com/refacto-drug.htm
National Hemophilia Foundation: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=179&contentid=45&rptname=bleeding